

Philippe Merle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6333976/publications.pdf>

Version: 2024-02-01

32
papers

12,836
citations

361413

20
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

9424
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 38-47.	7.7	20
2	First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers. <i>Liver Cancer</i> , 2022, 11, 268-277.	7.7	7
3	Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. <i>Liver Cancer</i> , 2022, 11, 558-571.	7.7	6
4	Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021, 127, 865-874.	4.1	20
5	The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 238.	3.7	14
6	Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 180-192.	1.5	47
7	Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. <i>Liver Cancer</i> , 2021, 10, 240-248.	7.7	39
8	Impact of 2016 Enhanced Recovery After Surgery (ERAS) Recommendations on Outcomes after Hepatectomy in Cirrhotic and Non-cirrhotic Patients. <i>World Journal of Surgery</i> , 2021, 45, 2964-2974.	1.6	6
9	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 991-1001.	10.7	179
10	Pragmatic tools for the prediction and potential early diagnosis of hepatitis B virus-related hepatocellular carcinoma?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101722.	1.5	0
11	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	1.6	1,255
12	Restoration of RNA helicase DDX5 suppresses hepatitis B virus (HBV) biosynthesis and Wnt signaling in HBV-related hepatocellular carcinoma. <i>Theranostics</i> , 2020, 10, 10957-10972.	10.0	31
13	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	27.0	3,828
14	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 4795-4804.	7.0	58
15	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	3.9	26
16	Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a propensity score matched analysis of postoperative morbidity and oncological results. <i>Future Oncology</i> , 2019, 15, 2517-2530.	2.4	6
17	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 282-296.	10.7	1,202
18	Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2019, 71, 763-772.	3.7	31

#	ARTICLE	IF	CITATIONS
19	Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2019, 77, 20-28.	7.7	159
20	No-touch multipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. <i>Journal of Hepatology</i> , 2018, 68, 1172-1180.	3.7	79
21	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , 2018, 69, 353-358.	3.7	270
22	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	27.0	1,677
23	Hepatic venous pressure gradient after portal vein embolization: An accurate predictor of future liver remnant hypertrophy. <i>Surgery</i> , 2018, 164, 227-232.	1.9	8
24	Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT). <i>BMC Cancer</i> , 2018, 18, 844.	2.6	5
25	Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 412-412.	1.6	40
26	Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. <i>Liver International</i> , 2017, 37, 1122-1127.	3.9	60
27	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	13.7	2,771
28	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1624-1636.	10.7	595
29	Conformal radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma: is it safe?. <i>Future Oncology</i> , 2016, 12, 1577-1586.	2.4	8
30	Oncogenic role of the frizzled-7/ β -catenin pathway in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 43, 854-862.	3.7	154
31	Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, 1110-1122.	1.3	234
32	Reply to Rizzo et al.. <i>Liver Cancer</i> , 0, , .	7.7	0